Introduction
Natural killer (NK) cells are lymphocytes that act early in the immune response against virus-infected or tumortransformed cells and may have a role in allogeneic hematopoietic SCT (allo-HSCT). 1, 2 Although the most important criteria for donor selection is the match for HLA class I and class II, other relevant factors such as the receptors of NK cells are currently a major focus of ongoing research. The ability of NK cells to recognize and kill target cells is commonly determined by the action of different surface receptors that either trigger or inhibit NK activities. The inhibitory killer Ig-like receptors (iKIRs; that is, KIR2DL and KIR3DL) recognize MHC class I molecules and restrain NK cell activation. HLA group C2 alleles are the ligands for KIR2DL1 while HLA group C1 alleles are ligands for KIR2DL2/L3 and HLA-Bw4 for KIR3DL1. There are six members (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1) in the family of activating KIRs (aKIRs). KIR genes vary greatly between different individuals. Not all KIR haplotypes encode the six aKIR genes. Diverse KIR gene combinations can be simplified into two groups of genes often called haplotypes: A and B. The group A haplotype encodes mainly for inhibitory receptors and appears to carry KIR2DS4 as its only stimulatory gene while group B haplotypes have variable gene content including additional activating receptor genes. KIR2DS4 has eight alleles currently described: only 2DS4*001 encodes for a cell surface receptor while the remaining alleles, 2DS4*003, *004, *006, *007, *008, carry a deletion in the exon encoding the membrane-proximal extracellular domain altering their reading frame. 3 In humans, Shilling et al. 4, 5 showed that the NK cell receptor repertoire, which emerges after allo-HSCT is determined by the KIR genes in the donor cells. In these newly developing NK cells, which may be activated, the inhibitory signal from iKIRs could be lacking because of the absence of ligands on the recipient's cells. Even in fully matched HLA transplants, because of the 'missing ligands' NK cells may become uninhibited in the early post transplant period and lyse target cells when MHC class I are absent from recipients' cells. 6, 7 Recent advances in understanding of NK signaling have provided a hypothesis suggesting that allogeneic transplants selected for lack of recipient HLA ligands for donor iKIRs allow the development of allo-reactive donor-derived NK cells that could kill host tumor (GVL), because of the triggering effect of aKIR. When not impeded by the iKIRs, binding of the aKIRs to their ligands results in NK cell stimulation. Chen et al. 8 reported that presence of more aKIR genes in donors were associated with a lower transplant-related mortality (TRM) and a better survival. However, this NK reactivity may also have a negative effect on outcome: Gagne et al. 9 reported an increase of GVHD in unrelated transplantations when the donor has more aKIR. These data highlight the effect of donor-aKIR genes in allo-HSCT.
Several recent trials using KIR-ligand mismatch to exploit NK cell allo-reactivity in the allo-HSCT have yielded discrepant results. 10, 11 Some discrepancies may be explained by the inconsistent use of T-cell depletion. As donor, T cells may override NK cell effects. In this study, we assessed the relative effects of donor KIR and host environment on clinical outcomes for T-depleted unrelated allo-HSCT.
Materials and methods

Patients, donors and transplant characteristics
Samples from 75 donor-recipient pairs from unrelated donors HSCT performed to treat leukemia were provided by the First Affiliated Hospital of Soochow University. The individuals (150) were Chinese Han. The study protocol was approved by the local ethics committee, and all patients gave written informed consent for their participation in the study, which followed the ethical guidelines of the Declaration of Helsinki. The patients in this group had a median age of 25 and included 19 women and 56 men. All the patients were undergoing transplantation for CML (n ¼ 24), AML (n ¼ 19), ALL (n ¼ 29) and other malignancies (n ¼ 3). Selection of an unrelated donor for HSCT was based primarily on HLA matching. All of the 75 donor-recipient pairs were HLA-A, B, C, DRB1 and DQB1 low-resolution typing identical. Of the 75 cases, 15 had an allelic mismatch at the HLA-Cw locus by highresolution typing. Transplant characteristics for the 75 patients is shown in Table 1a . Acute and chronic GVHD were diagnosed according to standard criteria. Patients with grade 0 acute GVHD (aGVHD) were defined as no aGVHD while those with grade I-IV aGVHD were all classified into the aGVHD group. Relapse was defined as recurrence of disease after transplantation, as based on cytomorphological or histological criteria. TRM was defined as death without relapse. Overall survival (OS) rate was defined as the percentage of patients who were alive for a period of time between transplantation and death because of any cause.
KIR PCR amplification
Genomic DNA was extracted from PBMC using a Gentra Puregene Blood Kit (QIAGEN, Valencia, CA, USA), following manufacturer's instructions. KIR (17 loci) genotyping was performed by PCR with sequence-specific primers using a KIR Genotyping SSP Kit (Invitrogen, Carlsbad, CA, USA) to test for gene presence and absence. PCR amplification reactions were performed using a Perkin Elmer GeneAmp 9700 thermal cycler (Perkin Elmer, Waltham, MA, USA).
To identify KIR2DS4 allelic sequences, the KIR2DS4 gene was amplified from genomic DNA by PCR with two pairs of primers designed to yield overlapping amplicons covering most of the exons as described earlier. 12 Nested PCR was used to isolate KIR2DS4 alleles with and without a known exon 5 deletion in heterozygotes as described earlier. For individuals who carried both 2DS4-full-length allele and 2DS4-deleted variant, PCR products were cloned using the TOPO TA cloning kit (Invitrogen).
Killer Ig-like receptor sequencing Sequencing primers were positioned to obtain the sequence of both strands of each amplicon. 12 Sequencing was performed using Applied Biosystems' BigDye Terminator Ready Reaction mix according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). The reactions were purified using CleanSEQ (Agencourt Bioscience, Beverly, MA, USA) according to the manufacturer's protocol. Sequencing products were detected using an Applied Biosystems 3730XL DNA analyzer. Sample files were analyzed using Sequencher (Genecodes Corp., Ann Arbor, MI, USA) and Assign SBT 3.2.7 (Conexio Genomics, Applecross, Western Australia) software. The sequences were compared with locus-specific databases (ImmunoPolymorphismDatabase-KIR Release 2.0.0) of known KIR sequences 13 created using Library Builder software (Conexio Genomics) to identify alleles. In this report, the numbering of nucleotides and codons is based on ImmunoPolymorphismDatabase-KIR unless noted.
Haplotype assignment
Detection of at least one of the KIR B haplotype-defining loci (KIR2DL5, 2DS1, 2DS2, 2DS3, 2DS5 or 3DS1) in a sample dictated that the genotype contains at least one B haplotype. Such samples were assigned the genotype B/x. We assumed A/A haplotypes when the only activating gene present in an individual was KIR2DS4 and the sample lacked all KIR B loci.
Transplant grouping
Transplants were divided into two groups depending on the donor's KIR haplotypes: 
Allo-reactive inhibitory killer Ig-like receptors definition
Under normal circumstances, every NK cell with killing capacity must have an inhibitory receptor that recognizes at least one of the MHC class I gene products on the cell surface, and this does indeed appear to be the case.
14 NK cells from stem cell donors may have the capacity during the early recovery phase to react to missing ligands even in HLA completely matched unrelated recipients 6, 7 and have a capacity of killing target cells in HLA identical allo-HSCT. The combination of incoming aKIR signals with the lack of inhibition of NK cells tips the balance of NK regulation to favor the reactive state. 15 Therefore, we examined the alloreactive iKIRs in these 75 transplants. HLA-KIR mismatching status was determined using high-resolution HLA-B and HLA-Cw typing. Allo-reactive KIRs were defined as donor 2DL1 lacking HLA group C2 alleles on the recipient's cells as well as 2DL2/L3 lacking HLA group C1 alleles and 3DL1 lacking HLA-Bw4 alleles.
Real-time (RT) PCR analysis
Thirty of the 75 pairs were analyzed by RT-PCR. All the selected transplants carried allo-reactive iKIR in the donorvs-recipient direction. The donor samples were drawn before mobilization while the recipient samples at days þ 30, þ 60, þ 90, þ 120, þ 180, þ 360 post transplantation. The transplantations were divided into two groups: patients with grade 0 aGVHD were defined as no aGVHD group while those with grade I-IV aGVHD were all classified into the aGVHD group.
RNA samples were isolated using TRIzol reagent (Invitrogen) and were stored at À80 1C. RT-PCR was used for quantification of KIR2DL1, 2DS1, 3DL1, 3DS1 and the control ABL gene, using the primers and probes as published. 16 We used TaqMan MGB Probe (Applied Biosystems) to label RT-PCR products. The human house keeping gene, ABL, was used as a control to assess the quality and quantity of the RNA. To construct a standard curve for the quantification of each KIR transcript, for each assay, 10-fold dilutions were performed. Results showed that standard curves of KIR2DL1, 2DS1, 3DL1 and 3DS1 paralleled that of the ABL gene, suggesting the feasibility of using ABL gene-based standard curves. RNA was first reverse transcribed into cDNA using 2 mg/ml total RNA from nucleated cells. The resulting cDNA was used as templates for subsequent PCR amplification. Reactions were performed using the TaqMan Universal PCR Master Mix and DNA Engine Opticon 2 (MJ Research, Waltham, MA, USA).
The quantity of target gene (KIR) in an unknown sample was expressed as a KIR/ABL ratio. The final copy number of the target gene (KIR) was calculated by the following formula: (KIR/total ABL ratio Â 10 000). It was defined as the copy number of KIR gene in every 10 000 ABL gene copies from all of the nucleated cells in blood.
Statistical analysis
Comparison between two groups was performed using Fisher's exact test. We considered six outcomes in the analysis: OS, event free survival, relapse, TRM, aGVHD and chronic GVHD.
Kaplan-Meier and Log-rank tests were used to estimate the survival curve and compare the difference of death risk between transplants from KIR haplotype A/A and haplotype B/x donors. Compared with haplotype B/x group, relative risk (RR) of the other five events after HSCT from haplotype A/A donors and 95% confidence interval (CI) were estimated by cohort study.
Compared with 2DS4-deletion subgroup, RR of all the six outcomes after HSCT from 2DS4-full subgroup donors and 95% CI were estimated by cohort study.
Continuous variables were compared between groups by Mann-Whitney U-test.
The P-values o0.05 were considered statistically significant. Two-sided tests were used throughout all the analyses. The SAS software package (version 9.1.3; SAS Institute, Cary, NC, USA) was used for data management.
Results
Predicted killer Ig-like receptor alloreactivity in the recipient HLA typing of 75 donor-recipient pairs showed that 66 pairs (88. 0%) lacked at least one recipient HLA ligand for donor iKIRs, defined as having potentially allo-reactive KIRs. The percentage of transplants with 'missing ligands' in A/A group and B/x group was 88.6 and 87.5%, respectively. In A/A group, this percentage for KIR2DS4-full subgroup and KIR2DS4-deletion subgroup was 85.7 and 90.5%, respectively. Multivariate analysis was performed to examine the percentage of transplants with 'missing ligands' on clinical outcomes and there was no statistical difference.
Of the 66 pairs with potential allo-reactive KIR, 53 pairs had no C2 group allele in the recipient for donor KIR2DL1; 2 pairs, no C1 group allele for donor KIR2DL2 and/or 2DL3; and 24 pairs, no HLA-Bw4 in the recipient for donor KIR3DL1. As mRNA expression of 3DL2 is undetectable in most individuals, 16 KIR2DL1 and 3DL1 are the main potential allo-reactive iKIRs in Chinese Han populations.
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Killer Ig-like receptor genotyping A majority (139) of the 150 samples from the Chinese Han population (92.7%) were positive for KIR2DS4. Sequencing of most of the coding region of this gene identified four of the eight known KIR2DS4 alleles, KIR2DS4*00101, *003, *004 and *007. The KIR2DS4-deleted variants were found in 44% of the 150 individuals. Of the 139 2DS4 positive individuals, 66 were homozygous for the A haplotype and 73 were classified into the B/x group. In the A/A group, 12.1% (8 of 66) individuals had the KIR2DS4-deleted versions only, compared with 30.1% (22 of 73) in the B/x group. It has been reported that the 2DS4-deletion alleles have a 22-bp deletion in exon 5, which causes a frame shift, yielding a KIR2DS4 protein with loss of the transmembrane and cytoplasmic domains. The deletion alleles do not encode for a functional receptor but a soluble form of the protein that is potentially secreted. 3 We noticed the fact that the individual who is homozygous for the A haplotype and with two deleted version of KIR2DS4 may not have any KIR functional activating gene. In this study, a significantly decreased frequency of carrying two 2DS4-deleted variants was observed in g A/A individuals (8 of 66), who carried KIR2DS4 as the only aKIR gene, in comparison with the B/x group (22 of 73) (P ¼ 0.013), which was similar to the results reported by of Middleton et al. The analysis of killer Ig-like receptor haplotype in donor and clinical outcomes In this study, transplants from KIR haplotype B/x donors (n ¼ 40) showed a higher OS rate compared with those from haplotype A/A donors (n ¼ 35) (RR 3.1 (95% CI 1.1-8.6), P ¼ 0.007), a result also observed in another study 18 (see Figure 1 ). No statistical difference was observed in event free survival, relapse, TRM, aGVHD and chronic GVHD between the two groups (see Table 1b ).
The analysis of KIR2DS4 subtypes in haplotype A/A donors and clinical outcomes
Of the 75 recipient/donor pairs, 35 cases who received transplants from KIR haplotype A/A donors were then further analyzed. In transplants, when donors carried two KIR2DS4-full-length alleles (n ¼ 14), the aGVHD rate was much higher, compared with those in which the donors carried one or two 2DS4-deleted variants (n ¼ 21) (RR 9.0 (95% CI 1.2-66.9), P ¼ 0.01). The risk of grade III-IV aGVHD was also increased significantly in the KIR2DS4-full subgroup (5/14), compared with the 2DS4-deletion subgroup (0/21) (P ¼ 0.006). On statistical analysis, 2DS4-full-length homozygous donors had a significantly increased rate of aGVHD in unrelated donors transplants compared with the donors who carried one or two 2DS4-deleted varients. No statistical difference was observed in OS, event free survival, relapse, TRM and chronic GVHD. The transplant characteristics and clinical outcomes are shown in Tables 2a and 2b .
P=0.007
A a The donor 2DS4-full group was defined as transplants from KIR2DS4-full-homozygous donors; the donor 2DS4-deletion group was defined as transplants from KIR2DS4-deletion-homozygous or KIR2DS4-full/ -deletion heterozygous donors.
Table 2b
The clinical outcomes of the 2DS4-full subgroup (n ¼ Table 3 . For the 30 transplants, the mRNA expression of 2DL1 increased significantly in patients with aGVHD 30-90 days after transplantation compared with patients without aGVHD (P ¼ 0.021). The same difference was observed for 3DL1 (P ¼ 0.005). The results suggested the association of a high expression of KIR2DL1 and 3DL1 in early stages (oday 90) post transplantation with the occurrence of aGVHD (Figure 2 ). This conclusion was more obvious when the recipient/ donor pairs were all KIR haplotype A/A. A significant statistical difference of 2DL1 and 3DL1 copy numbers could be found by 90 days post transplantation between the groups with and without aGVHD (z ¼ 2.558, P ¼ 0.011) ( Table 4) .
Discussion
Recognition of MHC class I ligands by inhibitory NK receptors is a critical part of NK cell education or maturation and is required for NK cells to recognize missing ligand. 19, 20 Once engaged with classical MHC class I, the inhibitory KIR sends a signal to the NK cell that dominates over any activating signal and prevents NK cells from killing the MHC class I expressing cell. [21] [22] [23] Experiments in mouse models of BM graft rejection led to the knowledge that NK cells would kill any target cells that lacked MHC class I molecules. 24 It has been known for many years that NK cells have a predilection for killing hematopoietic cells in mismatched BMT. 25 In allo-HSCT, the inhibitory signal for donor's iKIRs could be lacking because of the absence of their HLA class I ligands on recipient's cells, resulting in NK cell stimulation as illustrated by the model of activating pathways. 26 Usually, the activation pathways are kept in check by signals coming from inhibitory receptors. 21, 22 In the absence or downregulation of self MHC class I on the target cells after HLA mismatched allo-HSCT, these stimulatory signals are no longer suppressed, resulting in NK cell responses including cytokine production and granule release causing cytotoxicity. 27, 28 The advantage for patients receiving T-celldepleted transplants in which the NK allo-reactivity exists in the graft-versus-leukemia direction has been described by Ruggeri et al. 29 In the absence of NK cell allo-reactivity in HLA-identical HSCT it appears to be due to 'missing ligands' in the recipients, 6, 7 as well as the presence of activating receptors' affinity to their ligands. 30 The combination of incoming aKIR signals with the lack of inhibition of NK cells in the post transplant period tips the balance of NK regulation to favor the reactive state. 15 The aKIR can deliver an activating signal, leading to IFN-g production, cytotoxicity and proliferation. 23, 31 In this study, we found that transplants from haplotype B/x donors who carried more aKIRs had a better OS, which was consistent with Chen et al. and Cooley et al. 8, 18 However, a recent study also confirmed that the production of IFN-g was associated with the incidence of aGVHD. 32 The role of NK cells in the pathophysiology of aGVHD remains to be elucidated. Acute GVHD is a T-cellmediated disease, but there is evidence showing that it can be modified by IFN-g production of NK cells and by the kinetics of KIR receptor reconstitution. 32 NK cells possessing more activating receptors were characterized by the ability to produce IFN-g and thus induce a strong cytolytic response. 8 The aKIR in donors was considered a potential high-risk marker for aGVHD. 9 Our results showed that 2DS4 full-length allele, as the only aKIR gene in donor, was closely related with an increasing risk of aGVHD, especially III-IV aGVHD, in group A/A. 33 When donors possessed two 2DS4-full alleles, there might be more functional activating receptors on their NK cells compared with those who possessed less 2DS4-full alleles. The NK cells, activated through missing ligand mechanisms, could thus create a setting in which T cells cause aGVHD. 34 For example, activated NK cells secrete IFN-g that contributes to DC activation and thus indirectly lead to antigen-specific T-cell priming. 35 CD 56 bright NK-cells also contribute directly to T-cell priming. 36 Besides, alloreactive NK cells might directly attack non-hematopoietic cells and so contribute to aGVHD. 37 It is illustrated that missing KIR ligands are associated with increased GVHD after unrelated donor allo-HSCT. 7 A recent study reported that a missing HLA-C2 ligand for donor inhibitory KIR2DL1 was significantly associated with an increased risk of acute GVHD. 38 Our findings provide evidence of an association of high expression of KIR2DL1/3DL1 in the early stage after transplantation with aGVHD. Although the effect of KIR expression on the occurrence of GVHD seemed significant in our study, this hypothesis needs to be further confirmed in an expanded cohort of patients.
In conclusion, the analysis of KIR genes in stem cell donors showed a reduced survival if transplanted with a donor who was KIR homozygous for haplotype A. Our findings showed a significant association of the expression of full-length KIR2DS4 or a high expression level of KIR2DL1/3DL1 in the early stages after allo-HSCT with aGVHD. Taken together, these results suggested that the combination of KIR and HLA genotyping could help select transplant donors and improve the outcome of transplantation. Dynamic detection of KIR2DL1/3DL1 expression would be beneficial for prediction of aGVHD after transplantation. In addition, one may ask whether transplants from KIR haplotype B donors would have a higher risk of GVHD because the donors have more aKIR genes. However, our study did not show much difference. A majority of these haplotype B consists of multiple genes coding for aKIR and although there was no difference in aGVHD, and OS rate was better. Table 4 The relationship of patient 2DL1, 3DL1 mRNA expression and aGVHD when both the donor and recipient are haplotype A homozygous (n ¼ 10) 
